文献速递神经免疫

血神经丝轻链作为多发性硬化疾病活动与治疗反应的生物标志物

Blood neurofilament light chain as a biomarker of MS disease activity and treatment response.
PubMed 文献 · Neurology · 2019-02-08

研究基于两项III期试验(FREEDOMS和TRANSFORMS)的589例复发缓解型多发性硬化患者及35例健康对照,评估血神经丝轻链(NfL)作为疾病活动、组织损伤及治疗反应生物标志物的价值。结果显示基线NfL水平患者高于健康对照,且与MRI病灶负荷相关,并能预测未来疾病活动、脑萎缩及残疾进展风险;芬戈莫德治疗6个月即显著降低NfL水平并持续至研究结束。

要点

  • 基线血NfL水平可预测新发/扩大T2病灶、复发和脑萎缩风险。
  • 芬戈莫德较安慰剂和IFN-β-1a显著降低血NfL水平,6个月即显现。
  • 血NfL是易获取的疾病演变和治疗反应生物标志物。

核心结论

  • 血NfL水平与临床和MRI疾病活动及神经轴索损伤相关,具有预后价值,支持其作为疾病演变和治疗反应的易获取生物标志物。

研究设计与样本

  • 研究测量了589例复发缓解型多发性硬化患者(来自芬戈莫德vs安慰剂FREEDOMS和IFN-β-1a TRANSFORMS III期研究)及35例健康对照的血NfL,并与临床和MRI结局比较。

主要发现

  • 基线NfL水平(pg/mL)患者高于健康对照(30.5和27.0 vs 16.9,p=0.0001),且与T2病灶负荷和钆增强T1病灶数相关(p<0.0001)。
  • 基线高vs低NfL水平与新发/扩大T2病灶数增加(均值比2.64 [1.51-4.60],p=0.0006)、复发(率比2.53 [1.67-3.83],p<0.0001)、脑体积损失(均值差-0.78% [-1.02至-0.54],p<0.0001)相关,与确认残疾恶化风险边缘相关(HR 1.94 [0.97-3.87],p=0.0605)。
  • 芬戈莫德治疗6个月即显著降低NfL水平(vs安慰剂0.73 [0.656-0.813],vs IFN 0.789 [0.704-0.884]),并持续至研究结束(vs安慰剂0.628 [0.552-0.714],vs IFN 0.794 [0.705-0.894];两项研究所有评估p<0.001)。

关键数值与推荐

  • 基线NfL≥30.5 pg/mL(患者中位水平)视为高NfL,与低NfL相比,新发/扩大T2病灶均值比2.64(95%CI 1.51-4.60,p=0.0006)。
  • 高NfL与复发率比2.53(95%CI 1.67-3.83,p<0.0001)和脑体积损失均值差-0.78%(95%CI -1.02至-0.54,p<0.0001)相关。
  • 芬戈莫德vs安慰剂NfL水平比值0.73(95%CI 0.656-0.813)在6个月,0.628(95%CI 0.552-0.714)在研究结束;vs IFN分别为0.789(95%CI 0.704-0.884)和0.794(95%CI 0.705-0.894)。

临床怎么用

  • 血NfL可作为复发缓解型多发性硬化疾病活动监测和预后评估的辅助生物标志物。
  • 系列血NfL检测有助于评估芬戈莫德等疾病修饰治疗的反应,6个月时即可观察到变化。
  • 结合MRI和临床评估,高基线NfL提示需更密切监测疾病活动。

局限性

  • 研究基于III期试验人群,结果外推至其他MS亚型或真实世界人群需谨慎。
  • NfL与确认残疾恶化风险的关联未达统计学显著性(p=0.0605)。
  • 未报告NfL检测方法的具体分析性能或不同检测平台间的可比性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the value of blood neurofilament light chain (NfL) as a biomarker of recent, ongoing, and future disease activity and tissue damage and its utility to monitor treatment response in relapsing-remitting multiple sclerosis. METHODS: We measured NfL in blood samples from 589 patients with relapsing-remitting multiple sclerosis (from phase 3 studies of fingolimod vs placebo, FREEDOMS and interferon [IFN]-β-1a, TRANSFORMS) and 35 healthy controls and compared NfL levels with clinical and MRI-related outcomes. RESULTS: At baseline, NfL levels (pg/mL) were higher in patients than in healthy controls (30.5 and 27.0 vs 16.9, p = 0.0001) and correlated with T2 lesion load and number of gadolinium-enhancing T1 lesions (p < 0.0001, both). Baseline NfL levels, treatment, and number of new or enlarging T2 lesions during the studies predicted NfL levels at the end of study (all p < 0.01). High vs low baseline NfL levels were associated (estimate [95% confidence interval]) with an increased number of new or enlarging T2 lesions (ratio of mean: 2.64 [1.51-4.60]; p = 0.0006), relapses (rate ratio: 2.53 [1.67-3.83]; p < 0.0001), brain volume loss (difference in means: -0.78% [-1.02 to -0.54]; p < 0.0001), and risk of confirmed disability worsening (hazard ratio: 1.94 [0.97-3.87]; p = 0.0605). Fingolimod significantly reduced NfL levels already at 6 months (vs placebo 0.73 [0.656-0.813] and IFN 0.789 [0.704-0.884]), which was sustained until the end of the studies (vs placebo 0.628 [0.552-0.714] and IFN 0.794 [0.705-0.894]; p < 0.001, both studies at all assessments). CONCLUSIONS: Blood NfL levels are associated with clinical and MRI-related measures of disease activity and neuroaxonal damage and have prognostic value. Our results support the utility of blood NfL as an easily accessible biomarker of disease evolution and treatment response.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Kuhle J, Kropshofer H, Haering DA, et al. Blood neurofilament light chain as a biomarker of MS disease activity and treatment response. Neurology. 2019. PMID: 30737333. doi:10.1212/WNL.0000000000007032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。